denileukin diftitox-cxdl (Lymphir)
denileukin diftitox-cxdl is an FDA-licensed reference biologic from Citius Oncology, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Lymphir denileukin diftitox-cxdl
Citius Oncology, Inc.
- Approved
- Aug 07, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for denileukin diftitox-cxdl, in chronological order.
Reference approval
Approval date of the reference denileukin diftitox-cxdl product.
1 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for denileukin diftitox-cxdl (Lymphir)?
No 351(k) biosimilars or interchangeable biosimilars referencing denileukin diftitox-cxdl are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.